Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.60 2.94% 21.00 3,218,570 16:35:13
Bid Price Offer Price High Price Low Price Open Price
20.80 21.30 21.25 20.20 20.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.35 -6.33 -1.50 91
Last Trade Time Trade Type Trade Size Trade Price Currency
16:46:21 O 50,000 20.875 GBX

Kromek (KMK) Latest News

More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
31/7/202112:43Kromek Group PLC4,844
21/8/201710:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

DateSubject
01/8/2021
09:20
Kromek Daily Update: Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 20.40p.
Kromek Group Plc has a 4 week average price of 15.13p and a 12 week average price of 12.63p.
The 1 year high share price is 25.10p while the 1 year low share price is currently 7.80p.
There are currently 431,851,820 shares in issue and the average daily traded volume is 5,368,892 shares. The market capitalisation of Kromek Group Plc is £90,688,882.20.
25/7/2021
17:16
aqc888: I agree Mick. The old system DARPA are using is completely outdated compared with what Kromek could have achieved here. Huge potential in so many settings for this detector. Kromek with their 2year head start on the competition (started work in 2018). With their various patented intellectual property the CEO and ST speak of. Plus Kromek having secured £10m worth of government research funding for the biological pathogen detector (funds that won’t be available to competitors). All of this give Kromek a huge first mover advantage. Their competitive advantage or “economic moat” as Warren Buffet would put it should be substantial. Glad I increased Kromek to 10% of my portfolio a few weeks ago. Hopefully plenty more rises to come. Worst case scenario - the biological pathogen detector results are a failure. In this case Kromek have already secured 75% of this years sales in the radiation, hospital scanner and security screening business. Any future sales of the biological pathogen detector aren’t priced into the share price and government funding paid for all of the R&D. So perhaps the share price falls on the disappointment. Best case scenario- Kromeks main products continue to perform well and the biological pathogen detector sales eclipse the rest of the business with the huge global demand successful trial results will certainly bring. In this case scenario a £1 valuation for Kromek would be an extraordinarily undemanding valuation, given 1years profit from the biological pathogen detector could equal Kromeks entire market cap. Very exciting weeks ahead. I can anticipate a lot of turbulence in the share price in the coming weeks before the pathogen detector results are due (coming months according to ST). Some shareholders will see the sharp rise in the share price and won’t be able to resist banking the profits. Doing this before the positive results are released by the independent NHS lab will be a big mistake.
17/7/2021
10:37
aqc888: I don’t think anyone should underestimate the difficulty in achieving what Kromek are trying to do with this machine. I remember reading an article a leading scientist in the field (I posted it previously but can’t remember where it was from) saying what a difficult task it was. Comparing it to finding a needle in a haystack. Personally I’d give it a 50:50 chance of working. The positivity from ST and constant positivity from the CEOs comments encourage me slightly. BUT since the potential earnings from the Biopathogen detector isn’t priced in to the share price AND Kromek haven’t used any of their own money to develop it (US&UK grants). It seems that Kromeks regular business is performing well by itself without this machine. So we are basically getting a free ride on a 50:50 chance of the detector actually working. A detector which will completely re rate the share price. I’ve increased my holding to just under 10% of my portfolio. I don’t like investing in individual companies at all like this but this is an exception and I’m very nervous about doing this. I’m up 17% so far on Kromek and keeping a very close eye on what’s going on here, can’t wait to hear the results
14/7/2021
11:47
dougmachin: QuePassa - I think you're chasing a red herring here. Ventilators were a potential that never came about. That's all. If you wanna beat KMK with a stick, I would say there's other ways to do it. Ventilators aren't a part of KMK's core business. Agreed, they probably never should have mentioned anything in an RNS unless it was actually 100% going to result in sales, as this leads to 'boy who cried wolf' affect. From the presentation, I've moved so far on from that RNS. It's history. Not KMK's finest moment. But a small blip that in no way has affected KMK's core business. The presentation showed a quality company with some really exciting possibilities. Let's see where the share price is, this time next year. I am watching and would now add more.
14/7/2021
09:12
dougmachin: Kromek GroupResearch note and CEO videoSymbol  KMK   Listing AIM    Share Price 16p    Mkt Cap £69m  Sector Tech '3-2-1...we have lift-off' for all of KMK's end markets The 19th July 2021 will hopefully 'go down' in UK history as the day Covid switched from being a pandemic to an endemic disease. Pent-up demand & acceleration of deferred OEM product launches should also provide a multi-year tailwind for Kromek's end markets of Medical Imaging, Security Screening, and Homeland Security. Furthermore, their airborne Covid detector is already making great strides, having commenced field trials in schools, airports (eg Teesside International) and other locations under a £1.25m project with funding from Innovate UK. Plus the device's efficacy is presently being clinically validated by 3rd party laboratories. Where it is demonstrating "very positive" performance in terms of sensitivity and specificity. In fact, comparable with 'gold standard' PCR tests. Today's FY21 results saw adjusted FY'21 EBITDA (pre share based payments) come in slightly better than our estimates at -£1.7m (vs ED -£1.9m) on turnover of £10.35m (ED £10.0m). Alongside net cash closing April at £7.4m (split cash +£15.6m, debt £8.2m), after Feb's £13.0m (gross) fundraise at 15p. We reiterate our 26p/share valuation based on the strong rebound in demand. Noting the stock at 16p trades on 4.1x FY22 EV/sales vs 5.0x for the sector, yet is set to grow materially faster over the next few years.
01/7/2021
21:00
aqc888: Who cares if the share price is a little up or down. When the results to the trial are out whatever ups or downs will be wiped out. If the results are positive, as the CEO says, I expect the share price to reach at least 30p by the end of the month. (With a little help from ST.) If the results are negative - Kromek just keep on ticking over - the medical, nuclear and security products will carry on selling. Share price will probably fall to 10-12p for a short while on the disappointment. I have a feeling I’ll kick myself for not buying more.
01/7/2021
07:53
aqc888: Share price is exactly mid way between recent highs and lows. The buys and sells of Kromek are all small amounts. Hopefully the results are released on Wednesday 14th and it’s a slow news day to get maximum media attention.. expect a follow up tip from Simon Thompson if the results are positive which will turbo boost the share price gains
24/5/2021
19:40
aqc888: Share price not looking good. Kromek need to get a company they are trialling their machine with to make a public statement about the trial and potential benefits of Kromeks Pathogen detector - an airport or airline or hospital trust etc. Look at the effect the news of the dog trial has had on the share price and what potential effect a large company could have by saying they are trying Kromeks machine out. Dogs can be used to sniff out cancer - but I don’t think they will be worrying cancer diagnosis companies. This pathogen detector - if it works - will not have sales effected by sniffer dogs. They have enough work on their plate with drugs & explosives... A complete red herring of a story. We all know the board are useless at communication. Just need to hold our nerve and find out if this machine really works or we’ve all been chasing a pot of gold at the end of a rainbow...
20/5/2021
11:20
b00mb0y: To all the positive bloggers on this share, no matter what is perceived as great news articles, the market simply disagrees. Share sells consistently outweigh share buys. MC dropping on a daily basis along with the share price Why would this happen if it was such a good company with such good prospects and world class products? Can anyone please explain that? If anything the share price should have hovered around the .155p / .175p figure. The spike and discount offer was simply manufactured. I write this simply because I have lost faith and belief in this company. Your views are welcome.
19/4/2021
21:16
aqc888: QuePassa, I see from Kromeks share price that it’s been battered for previous underachievements, probably including the ones you mention. Although other commentators dispute your points, I’d say that there is no doubt some justification behind why the share price has suffered, including some of your points. However, I’d point out at the beginning of the pandemic the number of ventilators was thought to be key in dealing with it. Later they were not seen as a useful tool in dealing with covid patients, so I’m not surprised Kromeks little foray into the ventilator business was a failure. What attracts me to Kromek is that it is a company that has been punished hard for its previous underachievements. If this biological pathogen detector is as good as we are lead to believe, then I can’t see how anything will stop the share price from exploding - and previous underachievements which are currently suppressing the share price will only make that explosion all the more spectacular! Only time will tell, but at the end of the year we will know whether we have a stake in a company with a unique and truly game changing device in fighting the pandemic - or a stake in a company which is no less or no more value than it is today.
05/4/2021
12:39
aqc888: I agree, the huge share price swings illustrate that people are unsure what to make of Kromek. I’m a bit sceptical about this biological pathogen detector. But Kromek do make cutting edge equipment in other areas so have track record of delivering market leading equipment. I just can’t get my head around why the media who's main story at the moment is the pandemic, haven’t picked up on this story. Also why haven’t airline executives/cruise companies etc been talking up this device to boost confidence in their own companies. Whilst I trust Simon Thompson’s research, it just doesn’t all seem to add up. I get some comfort from seeing how long the delay was to Moderna and BATMs share prices to rise, despite their progress with profitable products related to the pandemic, and hope the same is true of Kromek. I’m hoping that the CEO with his mainly science background (evidence based) might be waiting to see what the evidence of the devices performance is before screaming from the rooftops. I’m also a bit concerned that there is no director buying. (BATM directors made big purchases when the share price remained low) which encouraged me to increase my holding. With Kromek it seems like alot of faith in Simon Thompson and the word of the CEO are required. But even if the pathogen detector doesn’t work out, it’s still a company with a lot of other products. So hopefully not too much downside risk, but huge upside potential with an analyst from Simon Thompson’s article suggesting x2 years profit from Kromeks pathogen machine could be equal to Kromeks current market capitalisation. I think with a bit of tangible credibility behind this pathogen detector the share price will start rising
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 18:42:34